Search Results
Results for: NOVARTIS (Save this search)
Number of Results: 125
SECURA BIO ACQUIRES RIGHTS TO FARYDAK FROM NOVARTIS
Nevada, US-based commercial stage biopharmaceutical company Secura Bio, Inc. has acquired the global rights to Farydak (panobinostat) from Novartis for treating multiple myeloma, t...

Secura Bio Acquires Rights to Farydak from Novartis
14 March 2019 - Nevada, US-based commercial stage biopharmaceutical company Secura Bio, Inc. has acquired the global rights to Farydak (panobinostat) from Novartis for treating mul...

Clinigen to Acquire US Rights to Cancer Drug Proleukin
19 February 2019 - UK-based pharmaceutical and services company Clinigen Group plc (AIM: CLIN) has signed an agreement with Swiss drugmaker Novartis to acquire the US rights t...

CLINIGEN TO ACQUIRE US RIGHTS TO CANCER DRUG PROLEUKIN
UK-based pharmaceutical and services company Clinigen Group plc (AIM: CLIN) has signed an agreement with Swiss drugmaker Novartis to acquire the US rights to Proleukin (a...

Eyevance Pharmaceuticals Acquires Flarex from Novartis
26 October 2018 - US-based pharmaceutical company Eyevance Pharmaceuticals has acquired Flarex (fluorometholone acetate ophthalmic suspension) 0.1% from Swiss drugmaker Novartis AG...

LifeMax Acquires Worldwide Right to Clinical Stage Orphan Asset
28 August 2018 - US-based biotechnology company LifeMax Laboratories, Inc has inked an exclusive worldwide license from Swiss drugmaker Novartis Pharma AG for the right to develop,...

China´s Laekna Acquires Exclusive Worldwide Rights to Two Clinical Stage Oncology Assets
2 August 2018 - Chinese biotechnology company Laekna Inc has signed an agreement with Swiss drugmaker Novartis Pharma AG (NYSE: NVS) for exclusive global rights to develop and comm...

CHINA´S LAEKNA ACQUIRES EXCLUSIVE WORLDWIDE RIGHTS TO TWO CLINICAL STAGE ONCOLOGY ASSETS
Chinese biotechnology company Laekna Inc has signed an agreement with Swiss drugmaker Novartis Pharma AG (NYSE: NVS) for exclusive global rights to develop and commercialise two or...

GLAXOSMITHKLINE TO ACQUIRE NOVARTIS STAKE IN CONSUMER HEALTHCARE JV FOR USD 13BN
UK-based drugmaker GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) has reached an agreement with Swiss drugmaker Novartis for the buyout of Novartis' 36.5% stake in their Consumer ...

You can compare news articles by clicking on the tick buttons
1   2   3   4   5   6   7   8   9   10   11   12   13   >